PET Imaging Biomarkers in Early Spondyloarthritis

Abstract

Spondyloarthritis (SpA) encompasses a group of inflammatory rheumatic diseases characterized by involvement of the axial skeleton, peripheral joints, and entheses, often leading to significant morbidity. Early detection remains crucial for optimal management and prevention of irreversible structural damage. Positron emission tomography (PET) imaging biomarkers are emerging as valuable tools for identifying early inflammatory changes before radiographic manifestations. This review synthesizes recent scientific findings, elucidates the clinical utility of PET imaging in early SpA, and discusses its implications for diagnosis, risk stratification, and therapeutic monitoring in the context of current clinical guidelines.

Introduction

Spondyloarthritis is a heterogeneous group of chronic inflammatory disorders, including ankylosing spondylitis, psoriatic arthritis, and reactive arthritis. Early recognition is challenging due to nonspecific clinical features and delays in radiographic changes. PET imaging leverages molecular tracers to reveal active inflammation at a cellular level, offering potential to revolutionize early SpA diagnosis. This article critically examines the role of PET imaging biomarkers, with a focus on their mechanistic underpinnings, clinical relevance, and guideline-based applications in early SpA management.

Epidemiology / Disease Burden

The prevalence of SpA varies globally, affecting approximately 0.3–1.9% of the population, with the highest rates observed in populations with a high prevalence of HLA-B27. Early SpA frequently manifests in young adults, contributing to substantial socioeconomic burden due to functional impairment, decreased quality of life, and healthcare utilization. Delayed diagnosis, often spanning several years, exacerbates morbidity, underscoring the need for sensitive early detection modalities such as advanced molecular imaging.

Pathophysiology

SpA pathogenesis is multifactorial, involving genetic susceptibility (notably HLA-B27), environmental triggers, and immune dysregulation. Central to disease activity is enthesitis, characterized by inflammation at the insertion sites of tendons and ligaments. Cytokine-mediated pathways, particularly those involving TNF-α and IL-17, drive local and systemic inflammation, leading to progressive tissue remodeling, new bone formation, and ankylosis. PET imaging biomarkers, such as 18F-FDG, target metabolically active inflammatory cells, providing a window into these early pathogenic processes.

Risk Factors

Genetic predisposition, particularly HLA-B27 positivity, remains the strongest risk factor for SpA. Other contributors include a family history of SpA, preceding infections (notably gastrointestinal or genitourinary), and co-existing inflammatory conditions such as psoriasis or inflammatory bowel disease. Environmental and lifestyle factors, including smoking, further modulate disease risk and progression.

Clinical Features

Early SpA typically presents with insidious onset of inflammatory back pain, morning stiffness, and peripheral arthritis. Enthesitis and dactylitis are hallmark features, but extra-articular manifestations such as uveitis, psoriasis, and inflammatory bowel disease may also occur. The clinical overlap with other musculoskeletal disorders complicates the diagnostic process, emphasizing the need for sensitive and specific biomarkers.

Diagnosis

Traditional diagnostic criteria for SpA, including the Assessment of SpondyloArthritis International Society (ASAS) classification, rely on clinical, laboratory, and imaging findings. While MRI is currently the gold standard for detecting early inflammatory changes, it has limitations regarding sensitivity and specificity. PET imaging biomarkers, particularly 18F-FDG and novel tracers targeting immune cell activity, have demonstrated promising sensitivity in detecting subclinical enthesitis and synovitis. Studies have shown PET can identify metabolic activity in affected tissues prior to structural changes on conventional imaging, potentially enabling earlier intervention. However, standardization of PET protocols and interpretation criteria is needed to facilitate widespread clinical adoption.

Treatment & Management

Early intervention in SpA is associated with improved long-term outcomes. Current management strategies include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologic agents targeting TNF-α or IL-17 pathways. PET imaging may aid in monitoring treatment response, differentiating active from inactive disease, and optimizing therapeutic regimens. Quantitative assessment of PET biomarkers could support personalized medicine approaches, potentially guiding escalation or de-escalation of immunomodulatory therapy.

Recent Advances / Emerging Therapies

Recent research has expanded the repertoire of PET tracers beyond 18F-FDG, exploring agents targeting somatostatin receptors, integrins, and other immune cell markers. These advances improve specificity for inflammatory cell populations involved in SpA pathogenesis. Integration of PET with hybrid imaging modalities such as PET/MRI further enhances anatomical localization and tissue characterization. Ongoing trials are evaluating the prognostic value of PET biomarkers in predicting disease progression and response to novel targeted therapies, including JAK inhibitors and IL-23 antagonists.

Guideline Recommendations

Current international guidelines, such as those from EULAR and ASAS, primarily endorse MRI for early SpA imaging. However, they acknowledge the potential of advanced molecular imaging modalities, including PET, for research and in cases where MRI is inconclusive or contraindicated. Standardization of PET imaging protocols, validation of novel tracers, and incorporation of quantitative PET metrics into clinical algorithms are areas of active guideline development.

Conclusion

PET imaging biomarkers represent a promising frontier in the early diagnosis and management of spondyloarthritis, offering sensitive detection of inflammation before irreversible structural damage occurs. While evidence supports their utility in research settings, further validation and integration into clinical practice are needed. As molecular imaging technologies advance and become more accessible, PET biomarkers are poised to enhance personalized care, improve patient outcomes, and inform future therapeutic strategies in SpA.